Flare Therapeutics takes in $82m Series A

Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has raised $82 million in Series A financing.

ByIris Dorbian

13 May 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Flare Therapeutics takes in $82m Series A

Casdin Capital

Nextech Invest

Third Rock Ventures

Related articles